CMS Contemplates Role Of Responding To Device Safety Concerns
This article was originally published in The Gray Sheet
Executive Summary
CMS is pondering its responsibility to repeal coverage for medical services or devices when safety concerns surface, leading some to question whether such action could infringe on FDA turf
You may also be interested in...
CMS Floats Topics For Possible National Coverage Determinations
Off-label procedures with drug-eluting stents, atrial fibrillation ablation and minimally invasive bariatric surgery are among topics CMS is considering for future national coverage policy determinations, the agency said July 30
CMS Floats Topics For Possible National Coverage Determinations
Off-label procedures with drug-eluting stents, atrial fibrillation ablation and minimally invasive bariatric surgery are among topics CMS is considering for future national coverage policy determinations, the agency said July 30
Off-Label Drug-Eluting Stent Data Weak; Label Should Be Revised – Panel
FDA panel members recommended changes to drug-eluting stent labeling that would more clearly indicate differences between on- and off-label use. However, they found that the data was insufficient to make definitive conclusions about risks for unapproved applications, which account for the majority of stent placements